JPMorgan downgraded Novocure to Underweight from Neutral with a price target of $50, down from $99.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVCR:
- Novocure announces reimbursement of Optune with TMZ
- Novocure announces final patient enrolled in METIS study
- Novocure price target lowered to $130 from $135 at H.C. Wainwright
- Novocure reports Q4 EPS (36c), consensus (30c)
- Novocure: Final patient enrolled TTFields combo study to treat pancreatic cancer